Treatment of accelerated atheosclerosis with interleukin-2 receptor targeted molecules
OwnerD. Douglas Millerinventor
Life of this patent
Estimating the term…
Abstract
The invention features a method for treating a patient suffering from accelerated atherosclerosis in a patient suffering from vascular damage, e.g., damage caused by percutaneous transluminal coronary angioplasty (PTCA), heart transplantation, or coronary vein graft. The method includes administering to the patient a molecule which is capable of specifically binding to a interleukin receptor expressed on a cell of the patient which contributes to the process of accelerated atherosclerosis. The molecule is capable of decreasing the viability of the cells.
Claims11
A method for inhibiting accelerated atherosclerosis in a patient suffering from vascular injury, said method comprising administering to said patient a molecule which is capable of specifically binding to an interleukin-2 receptor expressed on a cell of said patient which contributes to the process of accelerated atherosclerosis, said molecule being capable of decreasing the viability of said cell, said molecule being a hybrid molecule comprising a first and a second portion joined together covalently, said first portion comprising a cytotoxin capable of decreasing cell viability and said second portion comprising interleukin-2 or an antibody capable of binding to the interleukin-2 receptor.
Dependencies are inferred from the claim text.